42 results on '"Zoulim, Fabien"'
Search Results
2. Liver health in hemophilia in the era of gene therapy
3. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort
4. Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide
5. Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis
6. Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo
7. Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome
8. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy
9. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
10. OS-022 Kinetics of immunedysfunction in liver transplanted patients and impact on clinical outcome
11. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204
12. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy
13. WED-410 Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort
14. WED-391 Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (save-d)
15. OS-120 Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
16. OS-091 Precision-cut liver slices as a pre-clinical model for the evaluation of host-targeting agents against hepatitis B virus and hepatitis delta virus infection
17. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)
18. SAT-371 No amino acid substitution in HBV PreS1, HDAg, or NTCP associated with suboptimal response to bulevirtide in combination with pegylated interferon alfa-2a treatment in participants with chronic hepatitis delta: results from MYR204 a phase 2b study
19. WED-395 Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta
20. A molecular standard for circulating HBV RNA detection and quantification assays in chronic hepatitis B patients
21. Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes
22. Co-Transcriptional Regulation of HBV Replication: RNA Quality Also Matters
23. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy
24. Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy
25. Helicases DDX5 and DDX17 promote Hepatitis B Virus transcription termination heterogeneity in infected human hepatocytes
26. The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD.
27. Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss.
28. Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
29. The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis.
30. G-quadruplexes control hepatitis B virus replication by promoting cccDNA transcription and phase separation in hepatocytes.
31. Hepatitis C virus cure from direct‐acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
32. Long‐term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir‐containing antiretroviral therapy.
33. Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss
34. WED-366 Characterization of BJT-778, an anti-HBsAg neutralizing monoclonal antibody for treatment of hepatitis B virus and hepatitis D virus infections
35. Sa1638 SAFETY AND EFFICACY OF REP 2139-MG AGAINST HBV / HDV COINFECTION WITH ADVANCED LIVER DISEASE
36. Protocol for isolating CD163+Kupffer cells from human liver resections
37. After the Storm: Persistent Molecular Alterations Following HCV Cure.
38. A molecular standard for circulating HBV RNA detection and quantification assays in patients with chronic hepatitis B.
39. TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism.
40. Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
41. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort.
42. Detection and Quantification of HBV Transcripts by Full-Length 5'RACE-PCR.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.